MediciNova Inc
MNOV
查看详细走势图
1.370USD
-0.050-3.52%
交易中 （美东）报价延迟15分钟
22.06M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.52%
5天
-12.18%
1月
-5.52%
6月
+9.60%
今年开始到现在
+4.58%
1年
-5.52%
查看详细走势图
TradingKey MediciNova Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
MediciNova Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业中等水平。增长潜力稳定。当前估值合理，在生物技术与医疗研究行业排名137/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价9.00。中期看，股价处于平稳状态。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
MediciNova Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
MediciNova Inc亮点
亮点风险
MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
业绩增长期
公司处于发展阶段，最新年度总收入409.66K美元
利润高增长
公司净利润处于行业前列，最新年度总收入409.66K美元
估值高估
公司最新PE估值-5.64，处于3年历史高位
机构减仓
最新机构持股10.68M股，环比减少3.69%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值196.80K
活跃度增加
近期活跃度增加，过去20天平均换手率0.31
分析师目标
根据
4
位分析师
买入
评级
9.000
目标均价
+533.80%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
MediciNova Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
MediciNova Inc简介
MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
公司代码MNOV
公司MediciNova Inc
CEOIwaki (Yuichi)
网址https://medicinova.com/
相关品种
